By the Peptevity Research Desk — vendor-neutral, evidence-graded. Scientific review: independent reviewer pending — how our review works.

What Are Peptides? An Evidence-Graded Guide

Direct answer

A peptide is a short chain of amino acids — typically 2 to about 50 residues — joined by peptide bonds, which makes a peptide essentially a small protein, just shorter than the ~50–100-residue threshold where biochemists start saying "protein" (StatPearls, NCBI NBK562260; Institute for Molecular Bioscience, UQ). The body makes thousands of its own peptides that act as hormones, neurotransmitters, immune molecules, and signals — insulin and oxytocin are peptides (NBK562260). Many peptides are FDA-approved prescription drugs (around 120 peptide medicines are on the market worldwide) (2024 FDA TIDES review, PMC11945313). But most peptides sold online as "research peptides" are not FDA-approved, rest on animal or cell-culture evidence rather than human trials, and are labeled "research use only — not for human consumption." This page explains the science plainly and links the evidence-graded detail. It is information, not medical advice.

A note on what this page is. This is a category overview, not a single-compound monograph, so it carries the not-medical-advice and research-use-only framing inline rather than in a per-compound status box. For the dated, compound-by-compound regulatory picture, the source of record is our living 2026 regulatory tracker. Peptevity sells nothing, recommends no vendor, and publishes no human-dosing or self-administration instructions. Many peptides discussed here are not FDA-approved for any use; see are peptides legal and our medical disclaimer and RUO statement.

Peptides, proteins, and amino acids — the plain-language version

Start with the smallest unit. Amino acids are the body's basic building blocks; each one carries an amino group and a carboxyl group, and 20 standard amino acids combine in different orders to build everything larger (NBK562260). String two or more amino acids together and you have a peptide.

The link between them is a peptide bond. When two amino acids join, a condensation (dehydration) reaction removes a water molecule and forms a covalent bond between the carboxyl group of one and the amino group of the next (NBK562260). That bond is unusually rigid — it has partial double-bond character and is more planar and more resistant to heat and denaturants than an ordinary single bond (NBK562260). It is the same bond, repeated, that builds peptides and full proteins alike.

So what separates a peptide from a protein? Length, and not much else. The common convention is that peptides run from 2 up to about 50 amino acids, while chains longer than that are called proteins (NBK562260). The exact cutoff is a matter of convention, not a hard law of nature — the Institute for Molecular Bioscience puts the boundary at "approximately 50–100 amino acids," and notes that most peptides in the human body are much shorter, "chains of around 20 amino acids" (IMB, UQ). A few useful sub-labels:

Term Rough length Note
Amino acid 1 The monomer / building block
Dipeptide 2 Two amino acids, one peptide bond
Oligopeptide ~3–20 A "few" amino acids
Polypeptide >20 (and up) A longer unbranched chain
Protein >~50 Long chains that fold into defined 3-D structures

One practical consequence of being short: peptides are usually less rigidly structured than proteins, which fold into elaborate secondary, tertiary, and quaternary shapes (Britannica: peptide vs protein). For most purposes, the right mental model is simple — a peptide is a small protein, and the dividing line is roughly where the chain gets long enough to fold into a stable structure of its own.

How peptides work in the body

Peptides are not exotic. The body manufactures its own peptides constantly and uses them as signaling molecules — chemical messages that tell cells what to do. The biology breaks into a few recurring roles (NBK562260):

  • Hormones. Many hormones are peptides. Insulin (51 residues) regulates blood glucose; glucagon raises it; oxytocin and vasopressin (ADH) are nine-residue peptides; secretin (27 residues) helped found the entire concept of a hormone. These travel through the blood and act on distant tissues (NBK562260).
  • Neurotransmitters and neuropeptides. Short peptides carry signals in the nervous system, modulating pain, appetite, mood, and stress (NBK562260).
  • Immune / antimicrobial peptides. The body makes its own antibiotics — defensins, cathelicidins, and dermcidin — produced by epithelium, neutrophils, and other cells to kill microbes directly (NBK562260).
  • Local growth and repair signals. Peptides act in paracrine and autocrine fashion — on neighboring cells or the cell that released them — influencing tissue growth and differentiation (NBK562260).

Mechanistically, most signaling peptides work by binding a receptor on the cell surface — frequently a G-protein-coupled receptor (GPCR) — which sets off a cascade inside the cell (NBK562260). This "lock-and-key" specificity is exactly what makes peptides attractive as drugs: a well-designed peptide can hit one receptor with high selectivity, and that is the logic behind the entire therapeutic-peptide field. It is also why a mechanistic finding — "compound X binds receptor Y in a dish" — is only the beginning of an evidence case, never the end of it (more on that below, and in our evidence-grading methodology).

The major categories of peptides

"Peptide" covers an enormous range, from a fully approved diabetes drug to a research-only sequence with no human-safety record. Sorting them by what they are claimed to do is the most useful way in. Below is a one-line framing of the categories Peptevity covers, with the honest evidence status flagged for each. We link the evidence-graded detail; where a compound is mentioned only in passing, we name it in plain text.

Healing / tissue-repair peptides

The peptides with the loudest "regeneration" reputation — BPC-157 and TB-500 chief among them — sit here. The defining feature of this category is a wide gap between reputation and evidence: the most-cited tendon, ligament, gut, and muscle findings are animal studies (mostly rats), not human trials (evidence-grading methodology). The marketing nickname "wolverine peptide" — usually a BPC-157/TB-500 pairing — captures the regeneration hype precisely; see our note on the so-called wolverine peptide, and the individual write-ups on the healing peptide BPC-157 and the tissue-repair peptide TB-500, plus the head-to-head BPC-157 vs TB-500 comparison. None of these is FDA-approved.

Growth-hormone secretagogues (GH peptides)

These peptides don't supply growth hormone — they nudge the pituitary to release its own. The body's natural trigger is growth-hormone-releasing hormone (GHRH), a 44-amino-acid hypothalamic peptide that binds receptors on pituitary somatotroph cells and drives pulsatile GH secretion (Endotext, NCBI NBK279056; GHRH review, PMC9923806). Synthetic analogs imitate that signal. The cleanest example is tesamorelin (Egrifta), a GHRH analog and the one FDA-approved peptide in this class, approved in 2010 to reduce excess visceral fat in HIV-associated lipodystrophy (FDA summary review, NDA 022505). Sermorelin is the GHRH(1-29) fragment and is also a known prescription product. The research-grade GH peptides commonly sold online — names like ipamorelin, CJC-1295, and MK-677 — are not FDA-approved for these uses and are discussed in research framing only; we do not publish protocols for them.

GLP-1 / metabolic peptides

This is the category with the strongest human evidence — and the most public attention. Incretin peptides act on metabolic receptors (GLP-1, and in newer agents GIP and glucagon) to improve glycemic control and drive weight loss. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are FDA-approved branded prescription drugs with large Phase 3 evidence bases — the rare peptides that reach our top evidence tier (evidence-grading methodology). The investigational frontier is retatrutide, Eli Lilly's GIP/GLP-1/glucagon triple agonist, which produced large mean weight loss in trials but is not FDA-approved as of June 2026 (Jastreboff et al., NEJM 2023). See the evidence-graded retatrutide monograph and its dedicated retatrutide side-effects breakdown.

Cosmetic / copper peptides

Peptides used in skincare are a category of their own, and one where the regulatory lane is different. GHK-Cu (copper tripeptide-1) is the headline example: it has limited but genuine human trial support for topical, cosmetic skin effects, while its systemic and injectable claims rest on animal and cell data (Pickart & Margolina, 2018, PMC6073405; Frontiers in Medicine, 2026). Topical copper peptide is permitted as a cosmetic ingredient; the injectable lane is not approved. Read the full picture in the GHK-Cu copper-peptide monograph.

Approved peptide medicines (the established lane)

It is easy to forget, amid the gray-market noise, that peptides are a mature drug class. Around 120 peptide drugs are on the market worldwide, with many more in development across major pharmaceutical pipelines (2024 FDA TIDES review, PMC11945313). The FDA has approved peptide drugs across cardiovascular, metabolic, oncology, endocrine, and other areas, and continues to approve new ones — two of the FDA's 50 novel-drug approvals in 2024 were peptides (PMC11945313; Al Musaimi, J Peptide Sci 2024). These are normal prescription medicines — not "research chemicals" — and they are the reason the word "peptide" should never be read as automatically experimental or automatically fringe.

The research-vs-approved reality (read this part)

The single most important thing to carry away from this page is that "peptide" is a chemistry word, not a safety or legality verdict. Insulin is a peptide. So is a sequence synthesized last week with no published human data. They share a bond type and nothing else about their risk profile. Two distinctions do almost all the work:

1. Animal/in-vitro evidence is not human evidence. A great deal of the peptide content online presents rodent studies and cell-culture findings as if they were proof of benefit in people. They are not. We grade every efficacy and safety claim by how strong the research is and in which species it was conducted, from strong human RCT evidence down to anecdote (evidence-grading methodology). Most "research peptides" never reach the top tiers, because the human trials simply do not exist. Understanding why animal evidence does not transfer to humans is the difference between reading this category honestly and being sold to.

2. "Available to buy" is not "approved for use." Most peptides sold online are not FDA-approved drugs, dietary supplements, or foods, and are sold under a "research use only — not for human consumption" label. That label is a legal category, not a marketing wink. The U.S. Department of Defense's Operation Supplement Safety program states plainly, for example, that BPC-157 "is an unapproved drug and cannot be legally prescribed or sold over the counter" (DoD OPSS). The compounding lane is narrow and, in 2026, actively shifting: on April 15, 2026 the FDA announced removal of 12 peptides from its interim 503A Category 2 list because the supporting nominations were withdrawn — a procedural change, not an approval (FDA — 503A bulks; Federal Register notice, docket FDA-2025-N-6895). A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 reviews whether to move a first group of peptides toward the 503A bulks list, with a second review group following by February 2027 (FDA PCAC calendar).

A third layer applies to athletes: many peptides are prohibited in sport at all times under the World Anti-Doping Agency's rules, regardless of their FDA status (WADA Prohibited List).

None of this is a blanket "just don't." It is the opposite: a refusal to flatten a Phase-3-evidenced metabolic drug and a single-rat-study healing peptide into the same sentence. Read the grade, read the species, read the date. For the full framing, see what "research use only" means, are peptides legal, and investigational vs approved peptides. Peptevity publishes no human dosing or self-administration instructions for any compound.

How to use this hub

Peptevity is built as a reference desk, not a coach or a clinic. This page is the top of the peptides silo; from here, follow the threads that match your question. Everything below links into the same vendor-neutral, evidence-graded, primary-sourced set.

The compound monographs — evidence-graded write-ups, claim by claim and species by species:

  • BPC-157 — the healing peptide leading the July 2026 FDA review.
  • TB-500 — the tissue-repair peptide, animal-heavy evidence.
  • BPC-157 vs TB-500 — the head-to-head comparison.
  • The "wolverine peptide" — the BPC-157/TB-500 hype nickname, examined.
  • GHK-Cu — the copper peptide where the topical and injectable lanes diverge.
  • Retatrutide — the investigational GIP/GLP-1/glucagon triple agonist.
  • Retatrutide side effects — the trial-reported adverse-event profile.

The framing pillars — the lenses to read every compound through:

The regulatory desk — dated status, not legal advice:

The how-to silo — strictly laboratory/research procedure, never human-use protocols:

Honest bottom line

A peptide is a short chain of amino acids — a small protein, joined by the same peptide bonds, just under the ~50-residue line where the word "protein" takes over (NBK562260; IMB, UQ). The body runs on its own peptides as hormones, neurotransmitters, immune molecules, and repair signals, and the pharmaceutical industry has turned that biology into roughly 120 approved medicines (PMC11945313). But the same word also labels a large gray-market catalog of compounds whose reputations run far ahead of their evidence and whose legal status is "research use only — not for human consumption." The discipline this whole site is built on is keeping those apart: grade the evidence, name the species, date the regulatory status, and never let "peptide" do the work of "proven" or "approved." Start with the monographs above, lean on the evidence-grading methodology, and watch the living 2026 regulatory tracker.

Frequently asked questions

What is a peptide, in simple terms? A peptide is a short chain of amino acids — typically 2 to about 50 of them — joined end to end by peptide bonds (StatPearls, NBK562260). It is essentially a small protein. The body makes thousands of its own peptides and uses them as chemical messengers, including hormones like insulin and oxytocin.

What is the difference between a peptide and a protein? Mostly length. Peptides are short amino-acid chains (commonly 2–50 residues); proteins are longer chains, conventionally above roughly 50–100 residues, that fold into defined three-dimensional structures (NBK562260; IMB, UQ). The exact boundary is a convention, not a hard rule. Both are built from the same building blocks and held together by the same peptide bonds.

How are peptides different from amino acids? Amino acids are the individual building blocks — the monomers. A peptide is what you get when two or more amino acids are linked together by peptide bonds through a water-releasing condensation reaction (NBK562260). One amino acid is a single unit; a peptide is a short string of them.

How do peptides work in the body? Most signaling peptides act as messengers: they bind a specific receptor on a cell — often a G-protein-coupled receptor — and trigger a response inside that cell (NBK562260). The body uses peptides as hormones, neurotransmitters, antimicrobial molecules, and local growth and repair signals.

Are peptides FDA-approved? Some are; many are not. Around 120 peptide drugs are FDA-approved or marketed worldwide — including semaglutide, tirzepatide, and tesamorelin — and the FDA continues to approve new ones (2024 FDA TIDES review, PMC11945313). But most "research peptides" sold online are not FDA-approved for any use and are labeled "research use only — not for human consumption." Approval status is per-compound and per-use; see the dated 2026 regulatory tracker and are peptides legal.

Are research peptides safe to use? Peptevity does not make use recommendations and publishes no dosing instructions. Safety is a per-compound, per-route question, and for most "research peptides" the human safety data is limited or absent — the evidence is largely animal or cell-culture (animal vs human evidence). Gray-market material is also made outside Good Manufacturing Practice, with no guarantee of identity, potency, or purity. See are peptides safe. This is information, not medical advice.

How we sourced this page

The science above is anchored to NCBI and peer-reviewed primary sources; every regulatory statement is tied to an FDA, Federal Register, WADA, or DoD primary source with the status date attached, per our evidence-grading methodology and sourcing and citation policy. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement. Nothing here is medical or legal advice; see our medical disclaimer and RUO statement.

Primary sources

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity.

Related on Peptevity

Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.